Clinical trials: Untreated
Esophageal Cancer, Gastric Cancer
Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005607
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- 4 sites in United States
- Sponsor
- Robert H. Lurie Cancer Center
Non-small Cell Lung Cancer
A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)
The primary purpose of this study is to examine the safety of volociximab (V) in combination with a standard treatment of carboplatin (C), paclitaxel (P), and bevacizumab (B) in subjects previously untreated with chemotherapy for…
- Trial name
- NCT00666692
- Testing
- M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Abbott
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
This phase II trial studies how well vosaroxin and cytarabine work in treating patients with untreated acute myeloid leukemia. Drugs used in chemotherapy, such as vosaroxin and cytarabine, work in different ways to stop the…
- Conditions
- Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Multilineage Dysplasia, Myeloid Sarcoma
- Trial name
- VITAL (NCT02658487)
- Testing
- Cytarabine, Vosaroxin
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Solid Tumor, Adult Central Nervous System Germ Cell Tumor
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them.
- Conditions
- Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor
- Trial name
- NCT00638898
- Testing
- busulfan, melphalan, topotecan hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Urothelial Carcinoma
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.
- Trial name
- IMvigor130 (NCT02807636)
- Testing
- Atezolizumab, Carboplatin, Gemcitabine
- Where
- 204 sites in United States, Australia and 33 more
- Volunteers
- 1,213 people
- Sponsor
- Hoffmann-La Roche
Follicular Lymphoma (FL)
Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma
Follicular lymphoma (FL) remains an incurable indolent B-cell lymphoma for many patients, and although rituximab-based chemoimmunotherapy can achieve high initial response rates, a substantial proportion of patients experience…
- Trial name
- FLOURISH (NCT07550855)
- Testing
- Sotoclax in combination with zanubrutinib and rituximab regimen
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sun Yat-sen University
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002678
- Testing
- dexamethasone, melphalan, prednisone
- Where
- 37 sites in United States, Canada
- Volunteers
- 595 people
- Sponsor
- NCIC Clinical Trials Group
Lung Cancer, Nonsmall Cell
Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC
Gefitinib is currently the standard-of-care for patients with activating-EGFR mutant advanced non-small cell lung cancer (NSCLC).
- Trial name
- FL-ALTER (NCT04028778)
- Testing
- Gefitinib, Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 310 people
- Sponsor
- Sun Yat-sen University
Melanoma
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in…
- Trial name
- RELATIVITY-127 (NCT05625399)
- Testing
- Nivolumab + Relatlimab, rHuPH20
- Where
- 149 sites in United States, Australia and 17 more
- Volunteers
- 579 people
- Sponsor
- Bristol-Myers Squibb
Chronic Lymphocytic Leukemia
Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.
This study is investigating the efficacy of PD-L1 and PD-L2 peptides in untreated CLL patients with unmutated IGHV gene status.
- Trial name
- NCT03939234
- Testing
- PD-L1, PD-L2 peptides with Montanide ISA51
- Where
- Denmark
- Volunteers
- 19 people
- Sponsor
- Lars Møller Pedersen
HBV, HCV
Non-interventional Study to Assess the Number of People With Untreated/Unknown HBV + HDV and HCV in South-East Austria
The HEAL-S study is a non-interventional study with retrospective data analysis. It consists of two parts. First a retrospective analysis based on nucleic acid testing (NAT) results will be performed.
- Conditions
- HBV, HCV, HDV, Coinfection
- Trial name
- HEAL-S (NCT06834178)
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- Vanessa Stadlbauer-Koellner, MD
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
This phase I/II trial studies the best dose and effect of belantamab mafodotin given together with lenalidomide and daratumumab in treating patients with multiple myeloma that has come back (relapsed), does not respond to…
- Conditions
- Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT04892264
- Testing
- Belantamab Mafodotin, Daratumumab, Dexamethasone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Large B Cell Lymphoma
Risk Adapted Therapy in Diffuse Large B Cell Lymphoma
This randomized phase II trial is studying two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell lymphoma.
- Trial name
- NCT03188198
- Testing
- rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mansoura University
Leukemia
Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia
RATIONALE: Classical chemotherapy does not cure advanced chronic lymphocytic leukemia (CLL) despite new drugs. Rituximab is a monoclonal antibody directed against CD20 surface antigen on B lymphocytes and leads to apoptosis of…
- Trial name
- LLC2007SA (NCT00645606)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 542 people
- Sponsor
- University Hospital, Tours
Leukemia
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or…
- Trial name
- NCT00844298
- Testing
- Nilotinib+mVPD
- Where
- 16 sites in South Korea
- Volunteers
- 91 people
- Sponsor
- Asan Medical Center
Leukemia
DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899366
- Testing
- microarray analysis, mutation analysis, immunologic technique
- Volunteers
- 49 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Multiple Myeloma and Plasma Cell Neoplasm
Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma
RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00008242
- Testing
- dexamethasone, doxorubicin hydrochloride, thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adenocarcinoma, Non-small Cell Lung Cancer
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
The purpose of this trial is to figure out what effects (good or bad) the investigational drug agent called Tarceva (erlotinib; OSI-774) has on women with previously untreated adenocarcinoma.
- Trial name
- NCT00137839
- Testing
- Erlotinib
- Where
- 3 sites in United States
- Volunteers
- 84 people
- Sponsor
- Pasi A. Janne, MD, PhD
B-cell Lymphoma, Burkitt Lymphoma
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
The overarching hypothesis for this study is that a safe and tolerable dose (i.e., the maximum tolerated dose) will be identified for loncastuximab tesirine in combination with dose-adjusted etoposide phosphate, prednisone…
- Trial name
- LONCA (NCT05270057)
- Testing
- Etoposide, Doxorubicin, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Medical College of Wisconsin
Lung Cancer
S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004137
- Testing
- filgrastim, carboplatin, paclitaxel
- Where
- 85 sites in United States
- Volunteers
- 88 people
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.